![Richard Williams](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Richard Williams
Direttore Tecnico/Scientifico/R&S presso CannBioRex Pharmaceuticals Corp.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Marc Feldmann | M | 79 |
Kennedy Institute of Rheumatology
![]() Kennedy Institute of Rheumatology Pharmaceuticals: MajorHealth Technology Part of University of Oxford, Kennedy Institute of Rheumatology is a research facility that focuses on studying host-microbe crosstalk in health and disease, with a particular emphasis on inflammatory bowel disease, colorectal cancer, and inflammatory arthritis. The Kennedy Institute of Rheumatology is based in Headington, UK. The institute employs advanced microscopy methods and cutting-edge technology to generate a wide variety of data, which is made available to researchers through the Research Informatics team. The facility aims to future-proof excellence for Bioimaging within Oxford, keeping it competitive with international research.
CannBioRex Pharmaceuticals Corp.
![]() CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | 6 anni |
Jonathan Rothbard | M | 72 |
CannBioRex Pharmaceuticals Corp.
![]() CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | - |
Nick DeMare | M | 69 |
CannBioRex Pharmaceuticals Corp.
![]() CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | 6 anni |
David Danziger | M | 67 |
CannBioRex Pharmaceuticals Corp.
![]() CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | 6 anni |
Roger Daher | M | 58 |
CannBioRex Pharmaceuticals Corp.
![]() CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | 6 anni |
Lawrence Pemble | M | 36 |
CannBioRex Pharmaceuticals Corp.
![]() CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | 6 anni |
Charanjit Bountra | M | 63 |
CannBioRex Pharmaceuticals Corp.
![]() CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | 6 anni |
Raphael Mechoulam | M | - |
CannBioRex Pharmaceuticals Corp.
![]() CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | 6 anni |
Lawrence Steinman | M | 76 |
CannBioRex Pharmaceuticals Corp.
![]() CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | 6 anni |
Grafico relazionale
Relazione in diverse aziende
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Canada | 9 | 100.00% |
Regno Unito | 1 | 11.11% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Richard Williams
- Contatti personali